A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.

Giselle L. Saulnier Sholler,Genevieve Bergendahl,Laurent Brard,Ajay P. Singh,Barry W. Heath,Peter M. Bingham,Taka Ashikaga,Barton A. Kamen,Alan Homans,Marni A. Slavik,Shannon R. Lenox,Timothy Higgins,William S. Ferguson

A phase 1 study of nifurtimox in patients with relapsed/refractory neuroblastoma.

2011

Giselle L. Saulnier Sholler
Genevieve Bergendahl
Laurent Brard
Ajay P. Singh
Barry W. Heath
Peter M. Bingham
Taka Ashikaga
Barton A. Kamen
Alan Homans
Marni A. Slavik
Shannon R. Lenox
Timothy Higgins
William S. Ferguson

The primary aim of this phase 1 study was to determine the maximum tolerated dose (MTD) and evaluate the safety of nifurtimox alone and in combination with cyclophosphamide and topotecan in multiple relapsed/refractory neuroblastoma pediatric patients. The secondary aim was to evaluate the pharmacok

Keywords:

Oncology
Neuroblastoma
Refractory
Topotecan
Diabetes mellitus
Pathology
Nifurtimox
Maximum tolerated dose
Internal medicine
Medicine
Cyclophosphamide
in patient
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations